Navigation Links
Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option
Date:12/2/2009

CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that in connection with its previously announced unit offering, the underwriters have exercised in full their over-allotment option and purchased an additional 637,500 units. Each unit is comprised of one common share and 0.4 of a common share purchase warrant, and was sold at a price of US$3.00 per unit. Each whole common share purchase warrant entitles the holder to acquire one common share of Oncolytics upon payment of US$3.50 for a five year period ending November 23, 2014, subject to an acceleration of the expiry date in certain circumstances. Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering. Canaccord Capital Corporation and Bloom Burton & Co. acted as Canadian co-managers for the offering.

Together with the units sold on November 23, 2009, the Company has issued an aggregate of 4,887,500 units consisting of 4,887,500 common shares and 1,955,000 common share purchase warrants for total gross proceeds of US$14,662,500.

Oncolytics intends to use the net proceeds from the offering to fund its previously announced Phase III combination REOLYSIN(R) and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers, its other clinical development and research and development activities, and for general corporate and working capital purposes.

"Completing this financing further strengthens our balance sheet and will allow us to proceed beyond the 80 patient first stage of enrollment in our Phase III clinical trial, while giving us improved flexibility in reviewing partnering options," said Dr. Brad Thompson, President and CEO of Oncolytics. "After giving effect to this financing, we have in excess of $36 million i
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... N.Y. , May 22, 2013  Empire ... license for a patent pending novel genomic biomarker ... molecular diagnostic test that could help in diagnosing ... prostate cancer.  Neuroendocrine prostate cancer ... (PCA) that can arise de novo, but more ...
(Date:5/22/2013)... and NEW ORLEANS , May ... the field of regenerative medicine, presented new data generated ... Analysis Group (a leading health economics consultancy) demonstrating the ... ulcers (DFU) and venous leg ulcers (VLU) place upon ... of this research, which reveal annual costs of up ...
(Date:5/22/2013)... , May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) ... the Second Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer ... programs on May 30 at 1:30 p.m. Eastern Time.  A ... available on the Investors page of the Cleveland BioLabs website ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Mold remediation could ... said that there is a way to cut down the ... on its latest post the details of a method ... money. , Mold could be prevented, My Cleaning Products said. ... company stated that a mold remediation must then be promptly ...
Breaking Biology Technology:Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced ... will present a,company update at the BioCentury NewsMakers ... on Thursday, September 6, 2007 at 10:30 a.m.,ET. ... webcast of the presentation,via the investor section of ...
... Thursday, September 6, 2007, SAN DIEGO, Aug. ... announced today that Neurocrine Biosciences will,present at the ... presentation takes place Thursday, September 6, 2007 at ... (PT). The presentation will be,simultaneously webcast and may ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ... its first patent by the Canadian Intellectual ... (Number,2,259,318), this issuance extends the coverage of ... issued in the United States,Japan, Germany, Italy, ...
Cached Biology Technology:Pressure BioSciences, Inc. Issued First Patent in Canada 2Pressure BioSciences, Inc. Issued First Patent in Canada 3
(Date:5/21/2013)... long time that some creatures evolve more quickly than ... But it may be that height plays a role, ... U. S. National Evolutionary Synthesis Center. , In ... journal Nature Communications , Lanfear and colleagues report ... a database of global patterns in plant height for ...
(Date:5/21/2013)... increasingly being considered in the management of natural ... that can help them recognize and respond to ... their lives. , Place-Based Conservation: Perspectives from ... the Pacific Northwest Research Station,s Linda Kruger, can ... The book is published by Springer Verlag and ...
(Date:5/21/2013)... stem cells in the blood often jump into ... cells that can fight off illness. But repeated ... potentially leading to the development of serious blood ... researchers led by biologists at the California Institute ... models, the molecule microRNA-146a (miR-146a) acts as a ...
Breaking Biology News(10 mins):Small but speedy: Short plants live in the evolutionary fast lane 2Keeping stem cells strong 2
... of 154 smokers who had surgery to remove early stage ... of their potentially curative operation, and more than one-third ... patients who started smoking again did so within two months ... University School of Medicine and published in the December issue ...
... of researchers from Arizona State University and Motorola Labs, ... sensors based on carbon nanotubes, microscopically small structures that ... devices detected the presence of heavy metal ions in ... the researchers developed a method for applying peptides to ...
... risky behavior for humans, it's healthy for honeybees: Queen ... produce more disease-resistant colonies than monogamous monarchs. , According ... 7 issue of the Proceedings of the Royal Society ... long perplexed apiculturists, especially since seeking out multiple mates ...
Cached Biology News:Successful lung cancer surgery not enough to break nicotine dependence in many smokers 2Successful lung cancer surgery not enough to break nicotine dependence in many smokers 3Motorola researchers develop selective sensors based on carbon nanotubes 2Queen bee promiscuity boosts hive health 2
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
NuCycl DAPI Kit Application: Flow Cytometry Reactivity: Human...
...
Biology Products: